Table 2.
Changes in the efficacy parameters at end of the follow-up period (week 24)
| Efficacy parameters | Change in lobeglitazone group at 24 weeks | Change in pioglitazone group at 24 weeks | ||||
|---|---|---|---|---|---|---|
| Normoalbuminuria | Micro-/macroalbuminuria | P value* | Normoalbuminuria | Micro-/macroalbuminuria | P value* | |
| HbA1c (%) | − 0.71 ± 0.61** | − 1.11 ± 0.54** | 0.008 | − 0.79 ± 0.60** | − 0.74 ± 0.84** | 0.778 |
| Creatinine (mg/dL) | 0.01 ± 0.09 | − 0.01 ± 0.11 | 0.418 | 0.02 ± 0.07 | 0.00 ± 0.09 | 0.447 |
| eGFR (mL/min/1.73 m2) | − 1.4 ± 6.9 | 0.9 ± 10.4 | 0.358 | − 1.5 ± 5.6 | 0.2 ± 8.6 | 0.358 |
| UACR (mg/g Cr) | 0.7 ± 9.4 | − 25.4 ± 174.3 | 0.511 | 1.3 ± 11.9 | 15.3 ± 209.9 | 0.726 |
| Weight (kg) | 1.1 ± 1.7** | 0.5 ± 3.0 | 0.399 | 0.8 ± 2.2** | 1.3 ± 2.6** | 0.320 |
| Systolic blood pressure (mmHg) | 1.3 ± 13.8 | − 2.4 ± 14.8 | 0.322 | 2.3 ± 13.2 | − 0.6 ± 13.1 | 0.328 |
| Diastolic blood pressure (mmHg) | − 1.7 ± 9.0 | − 3.8 ± 12.8 | 0.502 | 1.1 ± 9.2 | − 2.3 ± 10.9 | 0.153 |
| Total cholesterol (mg/dL) | 9.4 ± 24.4** | 4.8 ± 23.4 | 0.443 | 10.5 ± 22.7** | 12.4 ± 28.1** | 0.754 |
| Triglyceride (mg/dL) | − 14.9 ± 62.2** | − 10.6 ± 57.9 | 0.771 | − 19.0 ± 60.6** | − 10.3 ± 106.5 | 0.686 |
| HDL-cholesterol (mg/dL) | 4.9 ± 7.9** | 3.3 ± 7.8 | 0.404 | 7.3 ± 9.4** | 5.6 ± 10.2** | 0.448 |
Data are expressed as the mean ± SD
*Significant difference at P < 0.05 (normoalbuminuria vs. micro-/macroalbuminuria); **significant difference at P < 0.05 vs. baseline